Premium
Acute arterial cardiovascular events risk in patients with primary membranous nephropathy
Author(s) -
Alawami Mohammed,
Wimalasena Samadhi,
Ghashi Rajaie,
Alnasrallah Basil
Publication year - 2019
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.14146
Subject(s) - medicine , membranous nephropathy , diabetes mellitus , cohort , nephropathy , disease , statin , surgery , proteinuria , endocrinology , kidney
Background Venous thromboembolism is a well established risk in patients with primary membranous nephropathy (MN) due to deficiency in natural anti‐coagulants. Recent studies suggested a higher risk of arterial thrombotic events as well in this group. Aim To identify that risk in our cohort. Methods We reviewed the data of all patients who had biopsy proven primary MN at our institute between 2003 and 2013. Clinical data were retrospectively reviewed until November 2016. The cardiovascular (CV) events, including acute coronary syndromes and strokes were determined and included only if occurred after the diagnosis of the nephropathy. Results A total of 204 patients had biopsy proven MN. Follow up information was available for 166 patients. Thirty‐one patients (18.6%) developed CV events during follow up. Thirty‐eight per cent of total events occurred within 1 year of MN diagnosis. Forty‐two per cent of those who developed CV events were not on anti‐thrombotic medications and 60% were not on statin therapy. Male gender, age, diabetes and absence of statins therapy were associated with higher rates of CV events in this group. Conclusion There is an increased risk of arterial events in patients with primary MN. This risk is greatest in the first year of diagnosis. The risk should be highlighted in this group of patients and anti‐platelets and statin therapy should be considered especially during the initial phase of the disease.